Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fulcrum Therapeutics Inc (NQ: FULC )

2.970 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fulcrum Therapeutics Inc

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 23) AbbVie Inc. (NYSE: ABBV) (... 
Via Benzinga
Exposures Product Safety
10 Biggest Price Target Changes For Tuesday
Citigroup cut the price target on Wix.com Ltd. (NYSE:WIX... 
Via Benzinga
The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow
Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to dominate the headlines, with small- and mid-cap companies among... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Analyzing Fulcrum Therapeutics's Unusual Options Activity
On Thursday, shares of Fulcrum Therapeutics (NASDAQ:FULC)... 
Via Benzinga
Why Are Fulcrum Therapeutics Shares Trading Higher Today?
Fulcrum Therapeutics Inc (NASDAQ:FULC) is trading higher a... 
Via Benzinga
Stocks That Hit 52-Week Highs On Monday
Before 10 a.m. ET on Monday, 119 companies hit new 52-week highs. Noteables: The largest company by market cap to set a new 52-week high was Alphabet (NASDAQ:GOOG... 
Via Benzinga
The Week Ahead In Biotech (Aug. 15-21): Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow
Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to dominate the headlines, with small-... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Mid-Afternoon Market Update: Dow Drops 50 Points; IEC Electronics Shares Spike Higher
Toward the end of trading Thursday, the Dow traded down 0.14% to 35,435.25 while the NASDAQ rose 0.29% to 14,808.42. The S&P also rose, gaining 0.19% to 4,456.37. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Fulcrum Therapeutics Popped Again on Tuesday
Compelling clinical-trial data that could validate the company's unique approach to new drug development inspired a slew of analyst upgrades. 
Via The Motley Fool
Analyzing Fulcrum Therapeutics's Unusual Options Activity
On Tuesday, shares of Fulcrum Therapeutics (NASDAQ:FULC) ... 
Via Benzinga
Earnings Scheduled For August 10, 2021
Companies Reporting Before The Bell • Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its second quarter. • Fulcrum Therapeutics (NASDAQ:... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
66 Biggest Movers From Yesterday
Gainers Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) shares jumped 50.5% to close at $20.74 on Wednesday. The company, last month, priced its IPO at $11 per share. Dyadic... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2021
Upgrades According to Barclays, the prior rating for Albertsons Companies Inc (NYSE: 
Via Benzinga
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers CohBar (NASDAQ:CWBR) stock moved upwards by 68.21% to $2.17 during Wednesday's pre-market session. The company's market cap stands at $134.0 million. The... 
Via Benzinga
85 Biggest Movers From Yesterday
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers CohBar (NASDAQ:CWBR) shares incr... 
Via Benzinga
FULC Stock: The Trial News Sending Fulcrum Therapeutics Skyrocketing
Shares of FULC stock are skyrocketing higher today on reports of positive results for the company's sickle cell treatment trial. 
Via InvestorPlace
Mid-Afternoon Market Update: 3D Systems Surges On Upbeat Earnings; Katapult Shares Drop
Toward the end of trading Tuesday, the Dow traded up 0.49% to 35,274.95 while the NASDAQ fell 0.41% to 14,799.03. The S&P also rose, gaining 0.18% to 4,440.12. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Fulcrum Therapeutics Shares Are Soaring Today
Fulcrum Therapeutics Inc (NASDAQ: FULC) is surging higher Tuesday after the company reported results from its Phase 1 study of FTX-6058 for sickle cell disease showed... 
Via Benzinga
Fulcrum Stock Nearly Triples — Why Shares Went Gangbusters On Sickle Cell Drug
Fulcrum Therapeutics unveiled positive results for its sickle cell disease drug, and the biotech stock more than doubled to a 13-month high. 
Via Investor's Business Daily
Mid-Day Market Update: Crude Oil Rises Over 3%; comScore Shares Plummet
Midway through trading Tuesday, the Dow traded up 0.37% to 35,231.28 while the NASDAQ fell 0.62% to 14,767.78. The S&P also fell, dropping 0.01% to 4,432.24. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
54 Stocks Moving In Tuesday's Mid-Day Session
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) climbed 79.3% to $14.93 after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy... 
Via Benzinga
Here's Why Fulcrum Therapeutics Stock Is Shooting Higher Today
A positive trial readout suggests the company's new drug discovery engine has more potential than expected. 
Via The Motley Fool
Mid-Morning Market Update: Markets Open Higher; Sysco Tops Q4 Views
Following the market opening Tuesday, the Dow traded up 0.47% to 35,266.74 while the NASDAQ rose 0.04% to 14,866.20. The S&P also rose, gaining 0.28% to 4,444.54. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Fulcrum Shares Are Trading Higher As Candidate For Inherited Blood Disorders Shows Proof Of Mechanism, Biology In Early-Stage Study
Fulcrum Therapeutics Inc (NASDAQ: FULC) has announced positive interim results from the Phase 1 trial with FTX-6058 in healthy adult volunteers. FTX-6058 is... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Arcturus Therapeutics (NASDAQ:ARCT) shares rose 25.93% to $60.75 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.5... 
Via Benzinga
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures COVID-19
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.